Enlivex Therapeutics , a Hadasit Bio-Holdings portfolio company, today announced that the European Medicines Agency has granted orphan drug status to the Company's lead product candidate, ApoCell, for the prevention of Graft-versus-Host Disease . Previously, ApoCell received orphan drug designation from the U.S. Food & Drug Administration .
http://ift.tt/1zOvMnL
http://ift.tt/1zOvMnL
No comments:
Post a Comment